An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease
2019 ◽
Vol 34
(10)
◽
pp. 1633-1652
◽
Keyword(s):
Keyword(s):
Keyword(s):
2020 ◽
Keyword(s):
Keyword(s):
2018 ◽
Vol 1
(suppl_2)
◽
pp. 201-202
Keyword(s):
Keyword(s):
Keyword(s):